U.S. Markets closed

Much of CME Group negative news priced into stock, says Wells Fargo

After CME reported in-line Q1 results but its guidance deteriorated slightly, Wells Fargo doesn't recommend selling the stock, as it thinks that much of the negative news is already priced into the shares. The firm still expects the company's EPS to grow at a double digit rate over the next two years, and it thinks that concerns over high frequency trading are overdone. The firm keeps an Outperform rating on the stock.